Abstract: Compositions and methods for the treatment of topical infections such as onychomycosis are disclosed.

Abstract: A method of predicting the responsiveness of a subject having a disease to a treatment with an inhibitor of Indoleamine 2,3-dioxygenase 2 (IDO), an inhibitor of tryptophan 2,3-dioxygenase (TDO), or an inhibitor of the IDO/TDO pathway and/or an additional therapy comprises performing a genotype assay to determine the presence, absence or mutation of the Indoleamine 2,3-dioxygenase 2 (ID02) gene at the single nucleotide polymorphism (SNP) site rs4503084 and the SNP site rs10109853.

Abstract: A personal injury mitigation device for sensing a fall condition and responsively deploying a protective device in bathrooms or other elevated-risk spatial environments. A fall sensing system of the device includes a sensor and an analysis module that processes a signal from the sensor to determine whether a fall condition exists, and if so, transmits a trigger signal to a deployment system. The deployment system includes a stored energy system and an actuation system operable to release stored energy in response to receipt of the trigger signal. An impact mitigation device receives the released energy from the deployment system, which causes deployment of a protective device (such as an airbag) from a housing in which the protective device is stored in a compact state. In the deployed state, the protective device is operable to protect a person against injury due to impact resulting from a fall.

Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.

Abstract: A composition comprising a wound-closure material physically or chemically associated with an agent that reduces scarring and improves the integrity of skin and underlying tissue in a mammalian subject. Methods for reducing or eliminating scarring or improving mammalian skin integrity comprise closing a wound with a composition, such as a suture material associated with a PHD inhibitor molecule, e.g., 1,4-DPCA.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.

Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

Abstract: Compositions and methods for the treatment of cancer are disclosed.

Abstract: Methods and compositions are provided for diagnosing of autosomal-dominant polycystic kidney disease (ADPKD), chronic kidney diseases, kidney dysfunction, and preeclampsia in a subject, preferably in a urine sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein profile generated from the sample, of RhoB protein or peptide fragments thereof. Comparing the protein level(s) of the RhoB protein or peptide fragments thereof in the subject's sample with the level of the same protein or peptide(s) in a reference standard, permits the determination of a diagnosis of ADPKD and other said diseases, or the identification of a risk of developing ADPKD and other said diseases, or enables the monitoring of the status of progression or remission of ADPKD and other said diseases in the subject.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.

Abstract: Compositions and methods for the treatment of an autoantibody disease or disorder are disclosed.

Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

Abstract: Anti-RhoB antibodies, compositions comprising the same, and methods for the treatment of autoimmune and inflammatory diseases using the anti-RhoB antibodies are disclosed.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.

Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.

Abstract: Compositions and methods for treating diseases and disorders expressing tissue inhibitor of metalloproteinase-4 (TIMP-4) are provided.

Abstract: Compositions and methods for the treatment of cancer are provided.

Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.